Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA)
NCT02315027Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2012
- Primary completion
- Mar 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous mesenchymal stem cells in multiple system atrophy (MSA), sponsored by Mayo Clinic. Started Oct 2012; status: active, not recruiting.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT02315027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315027.